global: drug-resistant 'white plague' lurks among rich and poor

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update GLOBAL: Drug-Resistant 'White Plague' Lurks Among Rich and Poor Kate Kelland
April 3, 2012

Reuters (03.19.12) - Tuesday, April 03, 2012 The World Health Organization met recently to discuss the possible emergence of tuberculosis that is resistant to all known medicines, or "totally drug-resistant" TB. If it is considered a new class definition, TDR TB would add a new category to TB's evolution over the years from normal to multidrug-resistant (MDR), then extensively drug-resistant (XDR). Lucica Ditiu of WHO's Stop TB Partnership said all drug- resistant TB "is a totally man-made disease." "It came about because patients were treated badly - either with poor quality drugs, or not enough drugs, or with insufficient observation so the patient didn't finish the treatment course," she said. "Whether it's MDR, XDR or TDR TB, it doesn't make much difference to the patients," said Ditiu. "A lot of them will face a very, very unfortunate fate." Rates of drug-resistant TB are rising rapidly in Asia, Africa, and in some of the world's wealthiest cities, including London, now considered the "TB capital of Europe." In 2005, London lawyer-in-training Anna Watterson was diagnosed with MDR TB following months of treatment for regular TB. "My friends were really shocked," Watterson said. "Most of them had only heard of TB from reading Victorian novels." At the time Watterson was living in the northwest borough of Brent, home to a large immigrant community and pockets of poverty. Like many in London, she commuted using the subway system. She had also traveled to India years earlier. "We've become too complacent about TB, thinking it's gone away. But the reality is that until it goes away in the developing world, it's not going away anywhere," said Watterson.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg After a decade, global AIDS program looks ahead NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs NORTH KOREA: North Korea Sees Surge of Drug-Resistant Tuberculosis Experimental Gilead drug effective in early-stage leukemia trial Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research: June 14, 2013 India's Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud Antiretroviral regimen associated with less virological failure among HIV-infected children AHF Shareholder Advocates Challenge Gilead on Drug Pricing at AGM NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative 2012 US medicine sales show shifts by drug type
Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles. Information in this article was accurate in April 3, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.